Business Model Breakdown
How ASP Isotopes Inc Makes Money
ASPI
Annual Revenue
$8M
Profit Margin
0.0%
Employees
136
The Short Version
ASP Isotopes (ASPI) is a technology company focused on producing highly enriched stable isotopes and other specialized materials for advanced industries. It generates revenue by applying its proprietary separation technology to create high-value isotopes used in quantum computing, medical diagnostics, and nuclear energy applications. Additionally, through its subsidiary, it is developing a project to produce and sell liquid helium and liquefied natural gas (LNG). The company also has initiatives in enriching lithium for nuclear fuels. Its business model relies on intellectual property, high-tech manufacturing, and specialized project development to serve critical, niche global markets.
Where the Revenue Comes From
Sales of enriched stable isotopes for various high-tech applications (future primary stream)
Sales of liquid helium and LNG from Virginia Gas Project (expected 2026)
Potential future sales of enriched lithium for nuclear fuels
Who buys: Government entities, research institutions, pharmaceutical and medical companies, nuclear power generation facilities, and high-tech manufacturing firms (e.g., quantum computing hardware developers).
Why It Works (Competitive Advantages)
- ✔Proprietary technology for stable isotope enrichment (Intangible Assets/IP)
- ✔Strategic positioning in high-demand, critical material markets (e.g., quantum computing, medical isotopes, nuclear fuels)
- ✔Early mover advantage in specific niche applications
Economic Moat: Narrow (Intangible Assets/IP (proprietary technology for isotope separation), Cost Advantages (potential for lower-cost isotope production if scalable), Efficient Scale (high capital costs and specialized expertise create barriers to entry))
What Our Analysis Says
DVR Score as of April 10, 2026
ASP Isotopes (ASPI) continues to target high-value stable isotope markets (quantum computing, medical, nuclear) and has made operational progress on its Virginia Helium Project, completing Phase 1 drilling ahead of schedule, with production expected in 2026. A new collaboration for UK lithium enrichment further bolsters its strategic vision. However, material negative developments significantly outweigh these positives: the market capitalization has declined by approximately 42% since the last analysis, the FY2025 10-K filing is delayed (a major red flag), and the company has undergone significant share dilution. The lack of current financial transparency and clear path to profitability, combined with a negative P/E, renders ASPI a highly speculative investment with substantial financial and execution risks, despite its compelling long-term market opportunities.